Notwithstanding positive clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial resistance from PBMs. These insurers are often creating obstacles to reimbursement, like significant price criteria and approval processe